Zentiva confirms the closing of its previously declared acquisition of Alvogen’s Central and Eastern European (CEE) business. The deal adds to Zentiva’s commercial footprint in Poland, Romania and Bulgaria.

“With this acquisition, we bring together two of the leading branded generic and OTC businesses in the CEE region,” said Nick Haggar, Chief Executive Officer of Zentiva. “Our strengths and product portfolios complement each other perfectly, in line with Zentiva’s growth strategy. With our continued expansion into new markets and our winning team, we can deliver more high-quality and affordable medicines that people need every day.”

This acquisition also expands Zentiva’s production capacity with the Labormed Alvogen site in Bucharest, Romania.